patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Alnylam scores EU approval for RNAi drug Givlaari

Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy.

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari
FDA clears Alnylam’s second RNAi drug for rare disease

Alnylam was also responsible for the first – Onpattro (patisiran) – which was launched for rare disease hereditary ATTR amyloidosis last year with a $450, 000 per year price tag, dropping to $345,
Alnylam gains key NICE approval for Onpattro

Patisiran has shown in its main clinical study that it can halt or even improve potentially debilitating symptoms of this disease in the majority of patients.
Akcea gets first OK for Waylivra in rare triglyceride disorder

Onpattro (patisiran) product.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

20 for 2020 – Five pharma leaders to watch in 2020

So far, its first launch Onpattro (patisiran) has been growing pretty slowly.
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Its pivotal APOLLO trial showed nearly all patisiran-treated patients saw the disease halted or slowed, with more than half seeing their neuropathy reversed.
Deal Watch table for January 2014

Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
Pharma deals during January 2014

The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...